Wall Street Zen upgraded shares of GlucoTrack (NASDAQ:GCTK – Free Report) from a strong sell rating to a sell rating in a research note published on Saturday morning.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on GlucoTrack
GlucoTrack Trading Down 8.3%
Institutional Investors Weigh In On GlucoTrack
A number of institutional investors have recently bought and sold shares of the business. Ikarian Capital LLC purchased a new position in shares of GlucoTrack in the fourth quarter valued at about $177,000. Boothbay Fund Management LLC bought a new position in shares of GlucoTrack in the fourth quarter worth about $52,000. Finally, Bank of America Corp DE grew its position in shares of GlucoTrack by 102,125.0% during the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after purchasing an additional 4,085 shares in the last quarter. Hedge funds and other institutional investors own 10.92% of the company’s stock.
GlucoTrack Company Profile
GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.
Recommended Stories
- Five stocks we like better than GlucoTrack
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.
